Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.

ABSTRACT:

Purpose

To validate a previously characterized 10-gene signature in prostate cancer with implication to distinguish aggressive and indolent disease within low and intermediate patients' risk groups.

Methods

A case-control study design used to select 545 patients from the Mayo clinic tumor registry who underwent radical prostatectomy. A training set from this cohort (n = 359) was used to build a 10-gene model, based on high-dimensional discriminant analysis (HDDA10) to predict several endpoints of clinical patients' outcome. An independent set (n = 219) from the same institution was used as validation set.

Results

HDDA10 showed significant performance for predicting metastasis (Mets) (AUC 0.68, p = 6.4E - 6) and biochemical recurrence (BCR) (AUC = 0.65, p = 0.003) in t

SUBMITTER: Abou-Ouf H 

PROVIDER: S-EPMC11813503 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature